Ayman El-KATTAN (IFM Therapeutics)

Ayman El-Kattan is senior director, head of DMPK at IFM Therapeutics SITE. He is also adjunct Professor at the College of Pharmacy, University of Rhode Island SITE

  • J Med Chem. 2020;63:10879-10896. Optimizing the benefit/risk of Acetyl-CoA Carboxylase inhibitors through liver targeting. Huard K, Smith AC, Cappon G, Dow RL, Edmonds DJ, El-Kattan A, Esler WP, Fernando DP, Griffith DA, Kalgutkar AS, Ross TT, Bagley SW, Beebe D, Bi YA, Cabral S, Crowley C, Doran SD, Dowling MS, Liras S, Mascitti V, Niosi M, Pfefferkorn JA, Polivkova J, Préville C, Price DA, Shavnya A, Shirai N, Smith AH, Southers JR, Tess DA, Thuma BA, Varma MV, Yang X. PubMed
  • AAPS J. 2019;21:99. Reconciling human-canine differences in oral bioavailability: Looking beyond the Biopharmaceutics Classification System. Martinez MN, El-Kattan A, Awji E, Papich M. PubMed
  • Drug Metab Dispos. 2018;46:729-739. Navigating transporter sciences in pharmacokinetics characterization using the Extended Clearance Classification System. El-Kattan AF, Varma MVS. PubMed
  • Drug Metab Dispos. 2018;46:346-356. A study on pharmacokinetics of Bosentan with systems modeling, Part 1: Translating systemic plasma concentration to liver exposure in healthy subjects. Li R, Niosi M, Johnson N, Tess DA, Kimoto E, Lin J, Yang X, Riccardi KA, Ryu S, El-Kattan AF, Maurer TS, Tremaine LM, Di L. PubMed
  • Adv Drug Deliv Rev. 2017;116:92-99. Molecular properties associated with transporter-mediated drug disposition. Varma MV, Lai Y, El-Kattan AF. PubMed
  • Clin Pharmacol Ther. 2017;102:33-36. Extended Clearance Classification System (ECCS) informed approach for evaluating investigational drugs as substrates of drug transporters. Varma MV, El-Kattan AF, Feng B, Steyn SJ, Maurer TS, Scott DO, Rodrigues AD, Tremaine LM. PubMed
  • Pharm Res. 2016;33:3021-3030. Projecting ADME behavior and Drug-Drug Interactions in early discovery and development: Application of the Extended Clearance Classification System. El-Kattan AF, Varma MV, Steyn SJ, Scott DO, Maurer TS, Bergman A. PubMed
  • Clin Pharmacol Ther. 2017;101:406-415. Transporter-mediated hepatic uptake plays an important role in the pharmacokinetics and drug-drug interactions of Montelukast. Varma MV, Kimoto E, Scialis R, Bi Y, Lin J, Eng H, Kalgutkar AS, El-Kattan AF, Rodrigues AD, Tremaine LM. PubMed
  • Clin Pharmacol Ther. 2016; in press. Extended Clearance Classification System (ECCS) informed approach for evaluating investigational drugs as substrates of drug transporters.Varma MV, El-Kattan AF, Feng B, Steyn SJ, Maurer TS, Scott DO, Rodrigues AD, Tremaine LM. PubMed
  • Pharm Res. 2016;33:3021-3030. Projecting ADME behavior and drug-drug interactions in early discovery and development: application of the Extended Clearance Classification System. El-Kattan AF, Varma MV, Steyn SJ, Scott DO, Maurer TS, Bergman A. PubMed
  • Clin Pharmacol Ther. 2016;100:419-422. Highlights from the American Association of Pharmaceutical Scientists/ International Transporter Consortium joint workshop on drug transporters in absorption, distribution, metabolism, and excretion: from the bench to the bedside - clinical pharmacology considerations. Ronaldson PT, Bauer B, El-Kattan AF, Shen H, Salphati L, Louie SW. PubMed
  • J Clin Pharmacol. 2016;56 Suppl 7:S99-S109. Transporter-enzyme interplay: Deconvoluting effects of hepatic transporters and enzymes on drug disposition using static and dynamic mechanistic models. Varma MV, El-Kattan AF. PubMed
  • Chem Res Toxicol. 2016;29:545-63. Involvement of drug transporters in organ toxicity: The fundamental basis of drug discovery and development. Cheng Y, El-Kattan A, Zhang Y, Ray AS, Lai Y. PubMed
  • Pharm Res. 2015;32:3785-802. Predicting clearance mechanism in drug discovery: Extended Clearance Classification System (ECCS). Varma MV, Steyn SJ, Allerton C, El-Kattan AF. PubMed
  • Mol Pharm. 2013;10:4207-15. Quantitative prediction of renal transporter-mediated clinical drug-drug interactions. Feng B, Hurst S, Lu Y, Varma MV, Rotter CJ, El-Kattan A, Lockwood P, Corrigan B. PubMed
  • Curr Top Med Chem. 2013;13:776-802. Intestinal targeting of drugs: rational design approaches and challenges. Filipski KJ, Varma MV, El-Kattan AF, Ambler CM, Ruggeri RB, Goosen TC, Cameron KO. PubMed
  • Drug Metab Dispos. 2013;41:966-74. Quantitative prediction of repaglinide-rifampicin complex drug interactions using dynamic and static mechanistic models: delineating differential CYP3A4 induction and OATP1B1 inhibition potential of rifampicin. Varma MV, Lin J, Bi YA, Rotter CJ, Fahmi OA, Lam JL, El-Kattan AF, Goosen TC, Lai Y. PubMed
  • Expert Opin Drug Metab Toxicol. 2013;9:459-72. Model-based approaches to predict drug-drug interactions associated with hepatic uptake transporters: preclinical, clinical and beyond. Barton HA, Lai Y, Goosen TC, Jones HM, El-Kattan AF, Gosset JR, Lin J, Varma MV. PubMed
  • Pharm Res. 2013;30:1188-99. Mechanistic modeling to predict the transporter- and enzyme-mediated drug-drug interactions of repaglinide. Varma MV, Lai Y, Kimoto E, Goosen TC, El-Kattan AF, Kumar V. PubMed
  • Mol Pharm. 2012;9:3535-42. Characterization of organic anion transporting polypeptide (OATP) expression and its functional contribution to the uptake of substrates in human hepatocytes. Kimoto E, Yoshida K, Balogh LM, Bi YA, Maeda K, El-Kattan A, Sugiyama Y, Lai Y. PubMed
  • Curr Protoc Toxicol. 2012;Chapter 23:Unit 23.3.1-15. Renal transporters in drug disposition, drug-drug interactions, and nephrotoxicity. Feng B, El-Kattan AF, Radi ZA. PubMed
  • Drug Metab Dispos. 2012;40:1527-37. Physicochemical property space of hepatobiliary transport and computational models for predicting rat biliary excretion. Varma MV, Chang G, Lai Y, Feng B, El-Kattan AF, Litchfield J, Goosen TC. PubMed
  • Expert Opin Drug Metab Toxicol. 2012;8:723-43. Impact of drug transporter pharmacogenomics on pharmacokinetic and pharmacodynamic variability - considerations for drug development. Lai Y, Varma M, Feng B, Stephens JC, Kimoto E, El-Kattan A, Ichikawa K, Kikkawa H, Ono C, Suzuki A, Suzuki M, Yamamoto Y, Tremaine L. PubMed
  • Mol Pharm. 2012;9:1199-212. pH-Dependent solubility and permeability criteria for provisional biopharmaceutics classification (BCS and BDDCS) in early drug discovery. Varma MV, Gardner I, Steyn SJ, Nkansah P, Rotter CJ, Whitney-Pickett C, Zhang H, Di L, Cram M, Fenner KS, El-Kattan AF. PubMed
  • Drug Metab Dispos. 2012;40:1085-92. In vitro evaluation of hepatic transporter-mediated clinical drug-drug interactions: hepatocyte model optimization and retrospective investigation.Bi YA, Kimoto E, Sevidal S, Jones HM, Barton HA, Kempshall S, Whalen KM, Zhang H, Ji C, Fenner KS, El-Kattan AF, Lai Y. PubMed
  • Drug Metab Dispos. 2012;40:1007-17. Mechanistic pharmacokinetic modeling for the prediction of transporter-mediated disposition in humans from sandwich culture human hepatocyte data. Jones HM, Barton HA, Lai Y, Bi YA, Kimoto E, Kempshall S, Tate SC, El-Kattan A, Houston JB, Galetin A, Fenner KS. PubMed
  • Drug Metab Dispos. 2012;40:407-11. Differential modulation of cytochrome P450 activity and the effect of 1-aminobenzotriazole on hepatic transport in sandwich-cultured human hepatocytes. Kimoto E, Walsky R, Zhang H, Bi YA, Whalen KM, Yang YS, Linder C, Xiao Y, Iseki K, Fenner KS, El-Kattan AF, Lai Y. PubMed
  • J Pharm Sci. 2011;100:4974-85. Development of a new permeability assay using low-efflux MDCKII cells. Di L, Whitney-Pickett C, Umland JP, Zhang H, Zhang X, Gebhard DF, Lai Y, Federico JJ 3rd, Davidson RE, Smith R, Reyner EL, Lee C, Feng B, Rotter C, Varma MV, Kempshall S, Fenner K, El-Kattan AF, Liston TE, Troutman MD. PubMed
  • Mol Pharm. 2011;8:1303-13. pH-sensitive interaction of HMG-CoA reductase inhibitors (statins) with organic anion transporting polypeptide 2B1.Varma MV, Rotter CJ, Chupka J, Whalen KM, Duignan DB, Feng B, Litchfield J, Goosen TC, El-Kattan AF. PubMed
  • Curr Drug Metab. 2010;11:730-42. Targeting intestinal transporters for optimizing oral drug absorption. Varma MV, Ambler CM, Ullah M, Rotter CJ, Sun H, Litchfield J, Fenner KS, El-Kattan AF. PubMed
  • Bioorg Med Chem Lett. 2011;21:2725-31. Discovery of novel hepatoselective HMG-CoA reductase inhibitors for treating hypercholesterolemia: a bench-to-bedside case study on tissue selective drug distribution. Pfefferkorn JA, Litchfield J, Hutchings R, Cheng XM, Larsen SD, Auerbach B, Bush MR, Lee C, Erasga N, Bowles DM, Boyles DC, Lu G, Sekerke C, Askew V, Hanselman JC, Dillon L, Lin Z, Robertson A, Olsen K, Boustany C, Atkinson K, Goosen TC, Sahasrabudhe V, Chupka J, Duignan DB, Feng B, Scialis R, Kimoto E, Bi YA, Lai Y, El-Kattan A, Bakker-Arkema R, Barclay P, Kindt E, Le V, Mandema JW, Milad M, Tait BD, Kennedy R, Trivedi BK, Kowala M. PubMed
  • J Med Chem. 2010;53:1098-108. Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination. Varma MV, Obach RS, Rotter C, Miller HR, Chang G, Steyn SJ, El-Kattan A, Troutman MD. PubMed

PubMed

Rhode Island (United States)

EL-KATTAN AYMAN.jpg

Last update: April 2021